There’s a really helpful resource for patients, developed by several leading experts in EGFR-based therapy and specifically the very common skin toxicity associated with EGFR inhibitors like iressa, tarceva, erbitux, and some others. I’ve already described some early ideas about rash management (prior post) and a more recent medical education program video on the same subject (prior post here). This is a summary article (here) published in the free oncology journal The Oncologist, but I think that more important than the brief review article are the summary poster and brochure for patients. Rather than recapitulate the content myself, I’ll just reproduce them for you to view here (click on any of these images to enlarge).
Here’s the poster (also available as a pdf here):
The brochure for patients is below (or pdf here):
These materials are also offered free, so if you find them helpful, you may want to speak with your oncologist or another health educator and point them to the direction of this form.
In the meantime, it’s good to see some real protocols for management become established and now widely available.
Posted in: Epidermal growth factor receptor (EGFR)-based therapies, Lung Cancer, Rash and other side effects, Supportive care, Targeted Therapies, Activity and Side Effects
email to a friend
printer friendly
Thanks for posting these, Dr. West. My father has been taking Tarceva for a year now and still hasn’t found an effective way to deal with the dry skin and itching. I hope this information will help.
1 Comment
Login (Must Be Logged In To Comment)